An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Developed in consultation with clinicians and patients for an enhanced user experience
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Subscribe To Our Newsletter & Stay Updated
